×
Please click
here
if you are not redirected within a few seconds.
All
News
Maps
Images
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
CAN-201, a novel AAV gene therapy candidate with efficacy in models of Fabry disease
BioWorld MedTech
Fabry disease is a rare X-linked lysosomal storage disorder where a deficiency in α-galactosidase A (GLA) results in the pathological...
7 months ago
CANbridge Announces NDA Acceptance of CAN108 (邁芮倍®/LIVMARLI®) for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis (PFIC) by China's National Medical Products Administration
팜뉴스
BEIJING and BURLINGTON, Mass., Oct. 17, 2023 /PRNewswire/ -- CANbridge Pharmaceuticals Inc. (HKEX:1228), a global biopharmaceutical company,...
7 months ago
UMass Chan licenses rights to spinal muscular atrophy gene therapy program to CANbridge Pharmaceuticals
UMass Chan Medical School
UMass Chan Medical School has licensed the rights to develop and commercialize a novel second-generation gene therapy to treat spinal...
16 months ago
Mirum Pharmaceuticals and CANbridge Pharmaceuticals Enter into Exclusive Licensing Agreement to Develop and ...
Business Wire
CANbridge and Mirum Enter into Licensing Agreement to Develop and Commercialize Maralixibat for Rare Liver Diseases in Greater China.
37 months ago
Taiwan approves first and only treatment for rare genetic disorder
BioSpectrum Asia
CANbridge announces marketing approval of CAN108 (/LIVMARLI) in Taiwan for the treatment of cholestatic pruritus in patients with Alagille...
7 months ago
CANbridge reports positive results for glioblastoma therapy study
Labiotech.eu
CANbridge Pharmaceuticals Inc. has announced that its therapy for glioblastoma has shown a 67% survival rate at five years,...
14 months ago
CANbridge Gets Possibly Safer, More Effective SMA Gene Therapy |...
SMA News Today
CANbridge Pharmaceuticals has acquired exclusive global rights to develop, manufacture, and commercialize a second-generation gene therapy...
16 months ago
Puma-backed CANbridge's Nerlynx gets Chinese nod to treat breast cancer subtype
S&P Global
Puma Biotechnology Inc.'s licensing partner CANbridge Pharmaceuticals Inc. received approval from the National Medical Products...
48 months ago
CANbridge Pharmaceuticals Granted Orphan Drug Designation for CAN 106 for the Treatment of Myasthenia Gravis
Business Wire
BEIJING & BURLINGTON, Mass.--(BUSINESS WIRE)--CANbridge Pharmaceuticals, Inc. (1228.HK), a global biopharmaceutical company,...
18 months ago
June 2 Quick Takes: Kisqali cuts recurrence risk in broad breast cancer population
BioCentury
Data presented at the American Society of Clinical Oncology meeting showed adjuvant treatment with Kisqali ribociclib from Novartis AG...
11 months ago